Your session is about to expire
← Back to Search
Open-Label Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
Study Summary
This trial is studying the effectiveness and safety of SPN-812 in adults with ADHD and mood symptoms. It is an open trial, meaning that participants will know what medication they are receiving, and the
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 4 trial • 96 Patients • NCT04786990Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the enrollment for this research study still ongoing?
"Based on the information provided by clinicaltrials.gov, this particular trial is not currently accepting new participants. The initial posting date was January 1st, 2024, and it was last updated on December 15th, 2023. However, it's worth noting that there are presently 177 other studies actively seeking participants."
What is the level of safety associated with Open-Label Treatment for individuals?
"Given that Open-Label Treatment is already approved, our assessment at Power rates its safety as a 3 on a scale of 1 to 3. This rating reflects the Phase 4 trial status and the existing approval for this treatment."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger